Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
FDA encourages interested groups and individuals to submit information on specific medical and biological areas where novel biomarkers can be identified that would meaningfully advance drug development.
United StatesFood, Drugs, Healthcare, Life Sciences
In the February 13, 2015, Federal Register,
FDA issued a notice seeking information to facilitate development
and qualification of biomarkers in areas related to human drug
therapeutics, consistent with policy goals of the Prescription Drug
User Fee Act. FDA encourages interested groups and individuals to
submit information on specific medical and biological areas where
novel biomarkers can be identified that would meaningfully advance
drug development. The survey provides more detailed information
requests. Comments due April 14,
2015.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
